Matthew Goetz, MD

Matthew P. Goetz, MD, discusses the next steps for evaluating treatment with lasofoxifene.

Matthew P. Goetz, MD, discusses the background of the ELAINE-1 study examining lasofoxifene in patients with estrogen receptor-positive, HER2-negative metastatic breast cancer harboring estrogen receptor 1 mutations.

Matthew P. Goetz, MD, discusses recent data on estrogen receptor mutations in patients with breast cancer.

Matthew Goetz, MD, professor of oncology and pharmacology, Mayo Clinic, discusses a secondary analysis of the MONARCH 1 and MONARCH 2 clinical trials in breast cancer.